CGEN vs. ADMA

Last updated Apr 1, 2026

Compare and contrast key facts about Compugen Ltd. (CGEN) and ADMA Biologics, Inc. (ADMA).

Performance

CGEN vs. ADMA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Compugen Ltd. (CGEN) and ADMA Biologics, Inc. (ADMA). The values are adjusted to include any dividend payments, if applicable.

CGEN vs. ADMA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
CGEN Compugen Ltd.	39.22%	-0.00%	-22.73%	176.65%	-83.36%	-64.49%	103.19%	174.65%	-13.20%	-50.98%
ADMA ADMA Biologics, Inc.	-50.60%	6.36%	279.42%	16.49%	175.18%	-27.69%	-51.25%	67.36%	-25.55%	-37.30%

Fundamentals

Market Cap CGEN : $201.74M ADMA : $2.20B
EPS CGEN : $0.38 ADMA : $0.60
PE Ratio CGEN : 5.66 ADMA : 15.07
PS Ratio CGEN : 2.75 ADMA : 4.34
PB Ratio CGEN : 1.96 ADMA : 4.60
Total Revenue (TTM) CGEN : $72.76M ADMA : $510.17M
Gross Profit (TTM) CGEN : $63.51M ADMA : $292.77M
EBITDA (TTM) CGEN : $33.35M ADMA : $195.35M

Returns By Period

In the year-to-date period, CGEN achieves a 39.22% return, which is significantly higher than ADMA's -50.60% return. Over the past 10 years, CGEN has underperformed ADMA with an annualized return of -9.31%, while ADMA has yielded a comparatively higher 0.68% annualized return.

CGEN

• 1D: 7.04%
• 1M: 17.68%
• YTD: 39.22%
• 6M: 44.90%
• 1Y: 45.89%
• 3Y*: 44.77%
• 5Y*: -24.67%
• 10Y*: -9.31%

ADMA

• 1D: -1.53%
• 1M: -42.13%
• YTD: -50.60%
• 6M: -38.54%
• 1Y: -54.59%
• 3Y*: 39.63%
• 5Y*: 37.55%
• 10Y*: 0.68%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

CGEN vs. ADMA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CGEN

CGEN Risk / Return Rank: 65
CGEN Sharpe Ratio Rank: 64
CGEN Sortino Ratio Rank: 70
CGEN Omega Ratio Rank: 63
CGEN Calmar Ratio Rank: 66
CGEN Martin Ratio Rank: 61

ADMA

ADMA Risk / Return Rank: 7
ADMA Sharpe Ratio Rank: 5
ADMA Sortino Ratio Rank: 7
ADMA Omega Ratio Rank: 7
ADMA Calmar Ratio Rank: 11
ADMA Martin Ratio Rank: 3

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CGEN vs. ADMA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Compugen Ltd. (CGEN) and ADMA Biologics, Inc. (ADMA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	CGEN	ADMA	Difference
Sharpe ratio Return per unit of total volatility	0.63	-0.95	+1.59
Sortino ratio Return per unit of downside risk	1.59	-1.39	+2.98
Omega ratio Gain probability vs. loss probability	1.17	0.82	+0.35
Calmar ratio Return relative to maximum drawdown	1.14	-0.84	+1.98
Martin ratio Return relative to average drawdown	2.00	-1.86	+3.86
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

CGEN vs. ADMA - Sharpe Ratio Comparison

The current CGEN Sharpe Ratio is 0.63, which is higher than the ADMA Sharpe Ratio of -0.95. The chart below compares the historical Sharpe Ratios of CGEN and ADMA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	CGEN	ADMA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.63	-0.95	+1.59
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.23	0.63	-0.86
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.10	0.01	-0.11
Sharpe Ratio (All Time) Calculated using the full available price history	-0.08	0.01	-0.08

Correlation

The correlation between CGEN and ADMA is 0.23, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

CGEN vs. ADMA - Dividend Comparison

Neither CGEN nor ADMA has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

CGEN vs. ADMA - Drawdown Comparison

The maximum CGEN drawdown since its inception was -97.90%, which is greater than ADMA's maximum drawdown of -91.28%. Use the drawdown chart below to compare losses from any high point for CGEN and ADMA.

Drawdown Indicators

	CGEN	ADMA	Difference
Max Drawdown Largest peak-to-trough decline	-97.90%	-91.28%	-6.62%
Max Drawdown (1Y) Largest decline over 1 year	-34.38%	-66.18%	+31.80%
Max Drawdown (5Y) Largest decline over 5 years	-94.21%	-66.18%	-28.03%
Max Drawdown (10Y) Largest decline over 10 years	-97.28%	-87.33%	-9.95%
Current Drawdown Current decline from peak	-89.05%	-63.24%	-25.81%
Average Drawdown Average peak-to-trough decline	-75.71%	-52.91%	-22.80%
Ulcer Index Depth and duration of drawdowns from previous peaks	19.61%	29.86%	-10.25%

Volatility

CGEN vs. ADMA - Volatility Comparison

The current volatility for Compugen Ltd. (CGEN) is 18.65%, while ADMA Biologics, Inc. (ADMA) has a volatility of 31.94%. This indicates that CGEN experiences smaller price fluctuations and is considered to be less risky than ADMA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CGEN	ADMA	Difference
Volatility (1M) Calculated over the trailing 1-month period	18.65%	31.94%	-13.29%
Volatility (6M) Calculated over the trailing 6-month period	55.05%	44.54%	+10.51%
Volatility (1Y) Calculated over the trailing 1-year period	72.87%	57.47%	+15.40%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	108.68%	60.00%	+48.68%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	90.41%	69.12%	+21.29%

Financials

CGEN vs. ADMA - Profitability Comparison

The chart below illustrates the profitability comparison between Compugen Ltd. and ADMA Biologics, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

CGEN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Compugen Ltd. reported a gross profit of 63.80M and revenue of 67.33M. Therefore, the gross margin over that period was 94.8%.

ADMA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, ADMA Biologics, Inc. reported a gross profit of 88.82M and revenue of 139.16M. Therefore, the gross margin over that period was 63.8%.

CGEN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Compugen Ltd. reported an operating income of 56.04M and revenue of 67.33M, resulting in an operating margin of 83.2%.

ADMA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, ADMA Biologics, Inc. reported an operating income of 62.75M and revenue of 139.16M, resulting in an operating margin of 45.1%.

CGEN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Compugen Ltd. reported a net income of 56.85M and revenue of 67.33M, resulting in a net margin of 84.4%.

ADMA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, ADMA Biologics, Inc. reported a net income of 49.38M and revenue of 139.16M, resulting in a net margin of 35.5%.